April 4th, 2020

Next
A full text version of this article is available.
To access article obtain online access here or login
 
Title:
Effect of Danazol on the Pregnancy Rate in Patients with Unsuccessful in Vitro Fertilization-Embryo Transfer
Authors:  Chisei Tei, M.D., Toyohiko Miyazaki, M.D., Ph.D., Naoaki Kuji, M.D., Ph.D., Mamoru Tanaka, M.D., Ph.D., Kou Sueoka, M.D., Ph.D., and Yasunori Yoshimura, M.D., Ph.D.
  OBJECTIVE: To determine the effect of danazol on in vitro fertilization-embryo transfer (IVF-ET) patients who failed to conceive in previous attempts despite having embryos with optimal morphology, whether endometriosis is present or not.

STUDY DESIGN: In this prospective, randomized, controlled study, of 81 patients who experienced unexplained failures of IVF-ET despite having good-morphology embryos, 40 received danazol (400 mg/d orally for 12 weeks) following the unsuccessful IVF-ET cycle. The next IVF-ET was performed within three months of the first spontaneous ovulation after danazol administration. The remaining 41 patients constituted the control group, and in them the next IVF-ET was performed within six months after the previous failed cycle.

RESULTS: Conception occurred in 16 of 40 (40%) danazol-treated patients at the subsequent cycle and showed a significant increase when compared with 8 of 41 (19.5%) control subjects (P<.05), though the number of embryos with optimal morphology decreased after danazol treatment.

CONCLUSION: Danazol may be used for patients who have had repeated failures of IVF-ET despite having morphologically optimal embryos and may be useful for increasing receptivity of the endometrium in these patients. (J Reprod Med 1998;43:541-546)
Keywords:  danazol; pregnancy outcome; infertility, female; fertilization in vitro; embryo transfer
   
   
  Acrobat Reader 7.0 is recommended to properly view and print the article.
Reader can be downloaded from